Article Id:JPRS-PB-00001290 Title:A randomized, open-label, prospective, multicenter phase-III clinical trial of Elores in lower respiratory tract and urinary tract infections Category:Pharmaceutical Biotechnology Section:Research Article
Abstract
Audio Abstract
Authors
Pdf File
Citation
My Reference
Methodology
Abstract
Background: Lower respiratory tract infections (LTRIs) and urinary tract infections (UTIs) are the leading causes of death world-wide. Treatment of these infections require the use of antibiotics with enhanced activity against a broad spectrum of respiratory and urinary pathogens. This study was designed to study clinical and bacteriological efficacy as well as tolerability of ceftiaxone þ disodium edtate þ sulbactam (the novel Antibiotic Adjuvant Entity; Elores) in adult patients in the treatment of lower respiratory tract infections (LRTIs) and urinary tract infections (UTIs). Methods: A randomized, open-label, multicenter study was conducted on 297 patients which included 204 in UTIs and 93 in LRTIs. A total of 148 patients were there in Elores group with 102 cases of UTIs and 46 LRTIs; 149 in ceftriaxone group with 102 cases of UTIs and 47 LRTIs. The patients received 3e10 days of treatment with Elores 3.0 g twice daily and ceftriaxone 2.0 g twice daily in two divided doses. Results and discussion: Clinical cure rates in ITT (Intend to treat) populations of Elores were 83.33% (85/102), 91.30% (42/46) in the UTIs and LRTIs, respectively, and 34.31% (35/102), 31.91% (15/47) in the ceftriaxone group for UTIs and LRTIs, respectively. The corresponding bacterial eradication rates were 95% (57/60) and 97.05% (33/34) for Elores in the UTIs and LRTIs, respectively and 80.64% (50/62) and 71.42% (10/14) for ceftriaxone in the UTIs and LRTIs, respectively. Adverse reaction were observed in 20.59% (21/102) and 15.22% (7/46) in Elores groups of UTIs and LRTIs, respectively and 36.27% (37/102) and 31.91% (14/47) in ceftriaxone groups of UTIs and LRTIs, respectively. Conclusions: Results obtained in the present study, together with microbiological evaluation data suggest that Elores is more effective and safe antibacterial agent for the treatment of LRTIs and UTIs infections